• Adenovirus Service • AAV Service • Lentivirus Service • Retrovirus Service
Today, lung cancer is one of the leading causes of cancer-related deaths worldwide, especially lung adenocarcinoma (LUAD) in non-small cell lung cancer, which accounts for the majority of lung cancer cases. Although targeted therapy and immunotherapy have made significant progress in recent years, the high recurrence rate and drug resistance of lung cancer remain a huge challenge in clinical practice. Fortunately, scientists have never stopped exploring.
Around the world, about 162,000 people are struggling with cystic fibrosis (CF), a serious genetic disease. CF is an autosomal recessive genetic disease that severely shortens the lifespan of patients. It is caused by loss-of-function mutations in the CF transmembrane conductance regulator (CFTR) gene. These mutations affect the synthesis, folding, transport, and gating properties of the CFTR anion channel, thereby interfering with the transport of chloride and bicarbonate ions. Although modulatory drugs have made some progress in the treatment of CF, existing modulatory drugs are powerless for patients carrying specific mutations, such as those with the G542X mutation. Recently, a study published in iScience titled "Adenine base editing with engineered virus-like particles rescues the CFTR mutation G542X in patient-derived intestinal organoids" has brought new hope.
Autoimmune diseases are the result of the immune system "killing each other", and the core mechanism is the disorder of the immune system's self-recognition function, which leads to inflammatory response and tissue damage. There are more than 100 known autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, psoriasis, multiple sclerosis, type 1 diabetes, etc.
Recently, the U.S. Food and Drug Administration (FDA) officially approved a groundbreaking medical trial - using gene-edited pig livers to treat patients with liver failure! Patients with severe liver failure who cannot receive human organ transplants are temporarily connected to pig livers outside the body, which filter their blood. This is a huge breakthrough in the field of xenotransplantation, and it also brings new hope of survival to countless patients waiting for organ transplants.
Cancer treatment has always been the focus of scientists around the world. From traditional surgery and radiotherapy to today's targeted therapy and immunotherapy, every technological advancement has brought new hope to patients. However, the complexity of cancer requires us to continue to explore the molecular mechanisms behind it.
In the battlefield of cancer treatment, immune checkpoint inhibitors (ICI) are like a brave warrior helping immune cells to attack cancer cells more effectively. However, they also face an embarrassing dilemma: among all patients who receive treatment, only less than 20% of them can benefit from it. This means that most patients have to face the cruel reality of ineffective treatment after receiving treatment with hope. This low response rate has undoubtedly cast a shadow on cancer treatment, and it has also made scientists urgently look for new strategies to improve the effect of immunotherapy so that more patients can rekindle the hope of life.
Recently, researchers from the Technical University of Munich in Germany published a research paper titled "Engineered nucleocytosolic vehicles for loading of programmable editors" in the international top academic journal Cell. The study developed a new efficient and versatile virus-like particle (VLP) delivery vector, ENVLPE, which can deliver all major RNA-guided gene editing tools (CRISPR-Cas9, base editors, prime editors) to a variety of cell types in the form of RNPs. This delivery system avoids the risk of DNA integration and demonstrates excellent editing effects in primary human T cells and two inherited retinal disease mouse models, highlighting its therapeutic potential.
Alzheimer's disease (AD) is an age-related neurodegenerative disease characterized by progressive memory loss and cognitive dysfunction. It is characterized by amyloid β (Aβ) plaque deposition and neuroinflammation, which plays a central role in the pathogenesis of AD as it exacerbates Aβ and Tau pathology.
One of the key challenges in the field of gene therapy is the safe and effective introduction of transgenes into cells to cure or reduce the severity of a disease. Viral vectors have proven to be one of the most effective means of achieving this goal, taking advantage of the natural ability of viruses to invade and introduce their genetic material into human cells. As a result, viral vectors are being developed for the treatment of a variety of diseases, including monogenic syndromes and cancer, and can be delivered in vivo, in situ, and ex vivo (cell therapy).
Plasmids as Biologics
